ESTRO 2025 - Abstract Book

S1297

Clinical - Lung

ESTRO 2025

Material/Methods: We expose a series of 13 patients (4 women, 9 men), average age 71.13 years old, diagnosed of LS-SCLC between May 2018 and October 2023, treated with a moderate hypofractionated radiotheraphy scheme. 21 daily-fractions of 3Gy were delivered with a total dose of 63Gy (BED 81.9Gy, EQD2 68.25Gy) , at beginning of platinum-etoposide based chemotherapy (cycle 1-2), followed by prophylactic cranial irradiation (PCI) when considered; with hypocampal avoidance (HA) in selected cases. All treatment dose targeted to mediastinum were delivered with IMRT after CT-scan simulation and using also PET fusion when it was available. All treatment sessions were administered under IGRT control, as well as SGRT since 2019. Quarterly follow-up was implemented with whole body CT-scan and cranial MRI . We evaluated overall survival (OS), local control (LC), local progression-free survival and distant progression-free survival (D-PFS), as well as toxicities based on CTCAE V5.0. Data analysis was performed with Microsoft-Excel (2023) and IBM-SPSS (26.0).

Results: